Rapid Nutrition Plc · EURONEXT:ALRPD
Rapid Nutrition — Investor Presentation
15 slides from Rapid Nutrition's investor presentation
Slide 1: Building a Global HealthTech Platform for Personalized Nutrition & Immune Science
Global HealthTech Building a Global HealthTech Platform for Personalized Nutrition & Immune Science From premium nutraceuticals to AI-enabled, clinically validated wellness systems 01 Investor Presentation | ALRPD | Euronext Growth
Slide 2: Strategic Vision & Direction
Strategic Vision & Direction This presentation outlines the Company’s strategic vision and areas of focus as at the date of this presentation. It reflects management’s current objectives, priorities, and initiatives, which may evolve or change in response to market conditions, regulatory considerati
Slide 3: About The Company
About The Company Rapid Nutrition is dedicated to the research, development, and global distribution of premium health and wellness products grounded in scientific evidence. Its philosophy — “made by nature, refined by science” — underscores a commitment to quality, transparency, and efficacy. With
Slide 4: Leadership Team
Leadership Team Meet the experts shaping our category and growth Simon St Ledger Michael Zhu Carl Seletz Ruth Kendon Dr. David Hunter CEO & Executive CFO, Member of the Advisory Member Head of Research and Scientific Advisory Board Director Institute of Chartered Product Development Member Accountan
Slide 5: Company Identity Transformation
Company Identity Transformation CURRENT BUSINESS PROFILE PLATFORM DIRECTION Premium nutraceutical portfolio Precision wellness & immune science platform Global distribution footprint AI-driven personalization engine Patented antiviral formulation Direct-to-consumer and wholesale Clinically validated
Slide 6: Expanding Portfolio of Science-Backed Wellness Brands
Expanding Portfolio of Science-Backed Wellness Brands Rapid Nutrition builds and operates a growing portfolio of evidence-based nutrition and wellness brands, encompassing both flagship and select third-party offerings, leveraging in-house innovation, natural science, and strategic partnerships to s
Slide 7: Why Personalized & Preventive
Why Preventive Healthcare Shift High-Value Demographics Personalized Global transition from reactive Attractive, high-value treatment to prevention consumer segments & Preventive Personalization Data Drives Wellness Replacing Mass Lifetime Value Supplements Personalization enables One-size-fits-all
Slide 8: Rapid Nutrition at an Inflection Point
Rapid Nutrition at an Inflection Point 1 Capital structure reset underway 2 AI integration inside existing revenue engine 3 Clinical validation through US-based studies 4 Expansion across APAC, USA and Europe 5 Platform monetisation pathways opening 08 Investor Presentation | ALRPD | Euronext Growth
Slide 9: From Products to Platform: RapidX
From Products to “The wellness economy has Platform: RapidX consistently grown faster than global GDP, and is Personalized wellness protocols projected to Monthly AI-designed supplement systems approach nearly US Integration of customer health data $9.8 trillion by 2029.” Real-world evidence generat
Slide 10: Science, IP & Clinical Credibility
Science, IP & Clinical Credibility Granted patents and proprietary Participation in large-scale Scientific advisory leadership Regulatory-compliant formulations US clinical studies development standards AS SEEN: As part of this groundbreaking $17.1 million international clinical trial, SystemLS is s
Slide 11: Multi-Engine Revenue Model
Multi-Engine Revenue Model Diversified revenue streams designed to support scalable and resilient growth 1. Product sales (direct-to-consumer and wholesale) 2. Personalized subscriptions 3. Practitioner & clinic channels 4. Licensing & IP partnerships 11 Investor Presentation | ALRPD | Euronext Grow
Slide 12: Disciplined, Platform-Led Acquisitions
Disciplined, Platform-Led Acquisitions Revenue: High-margin, $2–10m profitable Platform leverage potential post- Category acquisition adjacency 12 Investor Presentation | ALRPD | Euronext Growth
Slide 13: Investment Highlights
Investment Highlights In health markets, scalable science drives long-term value. 13 Investor Presentation | ALRPD | Euronext Growth
Slide 14: Near-Term Execution Priorities
Near-Term Execution Priorities AI Activation Science & Validation Geographic Expansion Personalized onboarding & Azurene clinical repositioning APAC and North America scale protocols Publication of existing study Subscription-led DTC AI-assisted pricing and summaries growth funnel optimisation Pract
Slide 15: Discover the Next Wellness Revolution Opportunity
Discover the Next Wellness Revolution Opportunity Stay up to date with Rapid Nutrition’s strategic priorities, portfolio evolution, and market developments. ir@rnplc.com www.rnplc.com +44 (0) 208 040 3498 15 Investor Presentation | ALRPD | Euronext Growth